These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 15778880)

  • 1. Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial.
    Freudenreich O; Herz L; Deckersbach T; Evins AE; Henderson DC; Cather C; Goff DC
    Psychopharmacology (Berl); 2005 Sep; 181(2):358-63. PubMed ID: 15778880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of donepezil adjunctive treatment to ziprasidone on cognitive deficits in schizophrenia: a double-blind, placebo-controlled study.
    Fagerlund B; Søholm B; Fink-Jensen A; Lublin H; Glenthøj BY
    Clin Neuropharmacol; 2007; 30(1):3-12. PubMed ID: 17272964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial.
    Keefe RS; Malhotra AK; Meltzer HY; Kane JM; Buchanan RW; Murthy A; Sovel M; Li C; Goldman R
    Neuropsychopharmacology; 2008 May; 33(6):1217-28. PubMed ID: 17625502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of low-dose donepezil in schizophrenia.
    Erickson SK; Schwarzkopf SB; Palumbo D; Badgley-Fleeman J; Smirnow AM; Light GA
    Clin Neuropharmacol; 2005; 28(4):179-84. PubMed ID: 16062097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beneficial effect of donepezil augmentation for the management of comorbid schizophrenia and dementia.
    Stryjer R; Strous RD; Bar F; Werber E; Shaked G; Buhiri Y; Kotler M; Weizman A; Rabey JM
    Clin Neuropharmacol; 2003; 26(1):12-7. PubMed ID: 12567159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial.
    Salloway S; Ferris S; Kluger A; Goldman R; Griesing T; Kumar D; Richardson S;
    Neurology; 2004 Aug; 63(4):651-7. PubMed ID: 15326237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia.
    Lee BJ; Lee JG; Kim YH
    J Psychopharmacol; 2007 Jun; 21(4):421-7. PubMed ID: 17092979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acetylcholinesterase inhibitor donepezil in the treatment of cognitive deficit in schizophrenia. Subanalysis of the active branch from Czech extended double blind study.
    Pérez M; Tůma I; Pytela O; Kadlecová E; Zemanová M; Lenderová Z
    Eur Psychiatry; 2006 Dec; 21(8):548-50. PubMed ID: 16797936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia.
    Friedman JI; Adler DN; Howanitz E; Harvey PD; Brenner G; Temporini H; White L; Parrella M; Davis KL
    Biol Psychiatry; 2002 Mar; 51(5):349-57. PubMed ID: 11904128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial.
    Doody RS; Ferris SH; Salloway S; Sun Y; Goldman R; Watkins WE; Xu Y; Murthy AK
    Neurology; 2009 May; 72(18):1555-61. PubMed ID: 19176895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-blind donepezil-placebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia: a pilot study.
    Risch SC; Horner MD; McGurk SR; Palecko S; Markowitz JS; Nahas Z; DeVane CL
    Schizophr Res; 2007 Jul; 93(1-3):131-5. PubMed ID: 17391930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Augmenting atypical antipsychotics with a cognitive enhancer (donepezil) improves regional brain activity in schizophrenia patients: a pilot double-blind placebo controlled BOLD fMRI study.
    Nahas Z; George MS; Horner MD; Markowitz JS; Li X; Lorberbaum JP; Owens SD; McGurk S; DeVane L; Risch SC
    Neurocase; 2003 Jun; 9(3):274-82. PubMed ID: 12925933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Donepezil for negative signs in elderly patients with schizophrenia: an add-on, double-blind, crossover, placebo-controlled study.
    Mazeh D; Zemishlani H; Barak Y; Mirecki I; Paleacu D
    Int Psychogeriatr; 2006 Sep; 18(3):429-36. PubMed ID: 16478570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
    Black SE; Doody R; Li H; McRae T; Jambor KM; Xu Y; Sun Y; Perdomo CA; Richardson S
    Neurology; 2007 Jul; 69(5):459-69. PubMed ID: 17664405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain injury, cognitive impairment, and donepezil.
    Whitlock JA
    J Head Trauma Rehabil; 1999 Aug; 14(4):424-7. PubMed ID: 10407214
    [No Abstract]   [Full Text] [Related]  

  • 17. Donepezil treatment of older adults with cognitive impairment and depression (DOTCODE study): clinical rationale and design.
    Pelton GH; Andrews H; Roose SP; Marcus SM; D'Antonio K; Husn H; Petrella JR; Zannas AS; Doraiswamy PM; Devanand DP
    Contemp Clin Trials; 2014 Mar; 37(2):200-8. PubMed ID: 24315979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Donepezil: a clinical review of current and emerging indications.
    Román GC; Rogers SJ
    Expert Opin Pharmacother; 2004 Jan; 5(1):161-80. PubMed ID: 14680445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of donepezil on cognitive functioning in Down syndrome.
    Johnson N; Fahey C; Chicoine B; Chong G; Gitelman D
    Am J Ment Retard; 2003 Nov; 108(6):367-72. PubMed ID: 14561111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapy of cognitive deficits in schizophrenia with acetylcholinesterase inhibitors. A systematic overview].
    Voss B; Thienel R; Leucht S; Kircher T
    Nervenarzt; 2008 Jan; 79(1):47-8, 50-2, 54-9. PubMed ID: 17960354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.